Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Aurélien Millet

Showing results (1-10 of 17) with videos related to

Pageof 2
Sort By:
Therapeutic Drug Monitoring|July 16, 2019
Determination of Cetuximab in Plasma by Liquid Chromatography-High-Resolution Mass Spectrometry Orbitrap With a Stable Labeled 13C,15N-Cetuximab Internal StandardAurélien Millet, Dorothée Lebert, Guillaume Picard, et al.
Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences|September 30, 2022
Quantification of canakinumab in human plasma by liquid chromatography-high resolution mass spectrometryAurélien Millet, Rémi Pescarmona, Alexandre Belot, et al.
Therapeutic Drug Monitoring|February 2, 2023
Evaluation of Limited Sampling Strategies for Bayesian Estimation of Daptomycin Area Under the Concentration-Time Curve: A Short CommunicationVianney Tuloup, Aurélien Millet, Alessandra Taricco, et al.
Molecules (Basel, Switzerland)|April 3, 2021
Development, Validation, and Comparison of Two Mass Spectrometry Methods (LC-MS/HRMS and LC-MS/MS) for the Quantification of Rituximab in Human PlasmaAurélien Millet, Nihel Khoudour, Dorothée Lebert, et al.
Clinical Pharmacokinetics|January 27, 2025
Exposure to Rifampicin and its Metabolite 25-Deacetylrifampicin Rapidly Decreases During Tuberculosis TherapySylvain Goutelle, Olivier Bahuaud, Charlotte Genestet, et al.
Biomedicines|June 2, 2021
Analysis of Pembrolizumab in Human Plasma by LC-MS/HRMS. Method Validation and Comparison with ElisaAurélien Millet, Nihel Khoudour, Jérôme Guitton, et al.
Antimicrobial Agents and Chemotherapy|November 7, 2025
Risk factors of daptomycin overexposure: a case-control studyClotilde Vellat, Romain Garreau, Aurélien Millet, et al.
The Journal of Antimicrobial Chemotherapy|January 15, 2025
Navigating the complexities of azole antifungal therapy through pharmacokinetic concepts: a case of prolonged isavuconazole toxicityManon Launay, Florian Saunier, Sarah Baklouti, et al.
Rheumatology (Oxford, England)|March 24, 2022
Safety of canakinumab during pregnancy: seven new casesEmmanuelle Weber, Aurélien Millet, Delphine Beghin, et al.
Talanta|December 31, 2020
Quantification of nivolumab in human plasma by LC-MS/HRMS and LC-MS/MS, comparison with ELISAAurélien Millet, Nihel Khoudour, Pauline Bros, et al.
Pageof 2

Showing results (1-10 of 17) with videos related to

Sort By:
Pageof 2
Therapeutic Drug Monitoring|July 16, 2019
Determination of Cetuximab in Plasma by Liquid Chromatography-High-Resolution Mass Spectrometry Orbitrap With a Stable Labeled 13C,15N-Cetuximab Internal StandardAurélien Millet, Dorothée Lebert, Guillaume Picard, et al.
Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences|September 30, 2022
Quantification of canakinumab in human plasma by liquid chromatography-high resolution mass spectrometryAurélien Millet, Rémi Pescarmona, Alexandre Belot, et al.
Therapeutic Drug Monitoring|February 2, 2023
Evaluation of Limited Sampling Strategies for Bayesian Estimation of Daptomycin Area Under the Concentration-Time Curve: A Short CommunicationVianney Tuloup, Aurélien Millet, Alessandra Taricco, et al.
Molecules (Basel, Switzerland)|April 3, 2021
Development, Validation, and Comparison of Two Mass Spectrometry Methods (LC-MS/HRMS and LC-MS/MS) for the Quantification of Rituximab in Human PlasmaAurélien Millet, Nihel Khoudour, Dorothée Lebert, et al.
Clinical Pharmacokinetics|January 27, 2025
Exposure to Rifampicin and its Metabolite 25-Deacetylrifampicin Rapidly Decreases During Tuberculosis TherapySylvain Goutelle, Olivier Bahuaud, Charlotte Genestet, et al.
Biomedicines|June 2, 2021
Analysis of Pembrolizumab in Human Plasma by LC-MS/HRMS. Method Validation and Comparison with ElisaAurélien Millet, Nihel Khoudour, Jérôme Guitton, et al.
Antimicrobial Agents and Chemotherapy|November 7, 2025
Risk factors of daptomycin overexposure: a case-control studyClotilde Vellat, Romain Garreau, Aurélien Millet, et al.
The Journal of Antimicrobial Chemotherapy|January 15, 2025
Navigating the complexities of azole antifungal therapy through pharmacokinetic concepts: a case of prolonged isavuconazole toxicityManon Launay, Florian Saunier, Sarah Baklouti, et al.
Rheumatology (Oxford, England)|March 24, 2022
Safety of canakinumab during pregnancy: seven new casesEmmanuelle Weber, Aurélien Millet, Delphine Beghin, et al.
Talanta|December 31, 2020
Quantification of nivolumab in human plasma by LC-MS/HRMS and LC-MS/MS, comparison with ELISAAurélien Millet, Nihel Khoudour, Pauline Bros, et al.
Pageof 2